Lewis, N., Cohen, R. B., Nishida, Y., Hurwitz, H. I., Arrowwood, C., Uronis, H. E., … Figueroa, J. (2008). 398 POSTER Phase I, pharmacokinetic (PK), dose-escalation study of EZN-2968, a novel hypoxia-inducible factor-1 alpha (HIF-1a) antagonist, administered weekly in patients (pts) with solid tumours. In European Journal of Cancer Supplements (Vol. 6, pp. 125–125). Elsevier BV. https://doi.org/10.1016/s1359-6349(08)72332-2

Lewis, N., R. B. Cohen, Y. Nishida, H. I. Hurwitz, C. Arrowwood, H. E. Uronis, F. Gamza, C. Longley, A. Buchbinder, and J. Figueroa. “398 POSTER Phase I, pharmacokinetic (PK), dose-escalation study of EZN-2968, a novel hypoxia-inducible factor-1 alpha (HIF-1a) antagonist, administered weekly in patients (pts) with solid tumours.” In European Journal of Cancer Supplements, 6:125–125. Elsevier BV, 2008. https://doi.org/10.1016/s1359-6349(08)72332-2.

Lewis N, Cohen RB, Nishida Y, Hurwitz HI, Arrowwood C, Uronis HE, et al. 398 POSTER Phase I, pharmacokinetic (PK), dose-escalation study of EZN-2968, a novel hypoxia-inducible factor-1 alpha (HIF-1a) antagonist, administered weekly in patients (pts) with solid tumours. In: European Journal of Cancer Supplements. Elsevier BV; 2008. p. 125–125.

Lewis, N., et al. “398 POSTER Phase I, pharmacokinetic (PK), dose-escalation study of EZN-2968, a novel hypoxia-inducible factor-1 alpha (HIF-1a) antagonist, administered weekly in patients (pts) with solid tumours.” European Journal of Cancer Supplements, vol. 6, no. 12, Elsevier BV, 2008, pp. 125–125. Crossref, doi:10.1016/s1359-6349(08)72332-2.

Lewis N, Cohen RB, Nishida Y, Hurwitz HI, Arrowwood C, Uronis HE, Gamza F, Longley C, Buchbinder A, Figueroa J. 398 POSTER Phase I, pharmacokinetic (PK), dose-escalation study of EZN-2968, a novel hypoxia-inducible factor-1 alpha (HIF-1a) antagonist, administered weekly in patients (pts) with solid tumours. European Journal of Cancer Supplements. Elsevier BV; 2008. p. 125–125.